Trio Solutions, LLC, a prominent player in the pharmaceutical consulting industry, is headquartered in the United States. Founded in 2010, the company has established itself as a trusted partner for pharmaceutical and biotech firms, offering specialised services in regulatory affairs, clinical development, and market access strategies. Fulcrum Pharma plc, based in the UK, complements Trio Solutions with its focus on drug development and commercialisation, particularly in the rare disease sector. Established in 2015, Fulcrum Pharma has made significant strides in advancing innovative therapies, leveraging its expertise to navigate complex regulatory landscapes. ADDPLAN GmbH, located in Germany, enhances this collaboration by providing cutting-edge software solutions for clinical trial planning and management. Founded in 2012, ADDPLAN is recognised for its unique approach to optimising trial designs, ensuring efficiency and compliance. Together, these companies form a robust alliance, driving advancements in the pharmaceutical landscape and delivering exceptional value to their clients.
How does Trio Solutions, LLC and Fulcrum Pharma plc and ADDPLAN GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Trio Solutions, LLC and Fulcrum Pharma plc and ADDPLAN GmbH's score of 33 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Trio Solutions, LLC, Fulcrum Pharma plc, and ADDPLAN GmbH, headquartered in the US, currently do not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. This lack of data suggests that the companies may not have publicly disclosed their carbon footprint or may be in the early stages of their climate reporting journey. Despite the absence of specific emissions data, these organisations are part of a merged entity under The Halifax Group, which may influence their climate commitments and reporting practices. However, no specific reduction targets or climate pledges have been outlined in the available information, indicating a potential area for development in their sustainability strategies. As part of the broader industry context, it is essential for companies like Trio Solutions, Fulcrum Pharma, and ADDPLAN to establish clear climate commitments and reduction initiatives to align with global sustainability goals. This could include setting Science-Based Targets (SBTi) or participating in initiatives such as the Carbon Disclosure Project (CDP) to enhance transparency and accountability in their climate actions.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| Scope 1 | 1,454,000 | 0,000,000 | 000,000 |
| Scope 2 | 2,000 | - | - |
| Scope 3 | 84,835,000 | 00,000,000 | 000,000,000 |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Trio Solutions, LLC and Fulcrum Pharma plc and ADDPLAN GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
